LB Pharmaceuticals Sees Schizophrenia Drug Derivative As New Option For US Patients

 
• By Joseph Haas
  
LB Pharmaceuticals hopes to bring a new formulation of an old schizophrenia drug to market (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas